A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery

The overall objective of this double blinded, randomized controlled trial (RCT) is to compare specific outcomes of three medications (Dexmedetomidine, Nicardipine, and Labetalol) which are routinely used to lower blood pressure used during general anesthesia for orthognathic (jaw) surgery. The outcome measures for the study will be surgical field visibility, estimated blood loss, hemodynamic parameters, operation time, and adverse events.
The specific objectives of this study are to compare:
1. Dexmedetomidine, Nicardipine, and Labetalol's effect on the quality of the surgical field. (Primary Outcome)
2. Dexmedetomidine, Nicardipine, and Labetalol's effect on estimated blood loss.
3. Dexmedetomidine, Nicardipine, and Labetalol's effect on hemodynamic parameters including systolic blood pressure, mean arterial pressure, and heart rate.
4. Dexmedetomidine, Nicardipine, and Labetalol's effect on operation time.
5. Dexmedetomidine, Nicardipine, and Labetalol's effect on adverse events.
The investigators will evaluate healthy adult male and female patients who require jaw surgery at Boston Medical Center. The anticipated 90 participants will be randomized into three groups: ) A Labetalol group in which the patients receive hypotensive anesthesia with the aid of labetalol, 2) A Nicardipine group in which the patients receive hypotensive anesthesia with the aid of nicardipine, and 3) A Dexmedetomidine group in which the patients receive hypotensive anesthesia with the aid of dexmedetomidine.
The time it will take for each individual participant ranges from 1-3 months. This time includes the pre-operative visit, the surgical procedure, a 1-week post-operation visit, and then followed for 30 days post-operatively after which the patient's participation in the study will conclude.

开始日期2025-03-01

申办/合作机构

Boston Medical Center

CTR20244831

/ Active, not recruitingN/A

盐酸拉贝洛尔片在健康成年受试者中空腹状态及高脂餐后单次口服给药的随机、开放、四周期、两序列、重复交叉设计生物等效性试验方案

主要研究目的：研究重庆圣华曦药业股份有限公司生产的盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹状态及高脂餐后以口服途径单次给药的药代动力学特征，并以Aspen Pharma Schweiz GmbH持有，Aspen Pharma Schweiz GmbH生产的盐酸拉贝洛尔片（商品名：Trandate®；规格：200mg）为参比制剂，进行生物等效性评价。次要研究目的：初步考察盐酸拉贝洛尔片受试制剂和参比制剂在健康受试者中的安全性。

开始日期2025-01-04

申办/合作机构

重庆圣华曦药业股份有限公司

NCT06752863

/ Recruiting临床4期IIT

Comparative Study of Labetalol Infusion Versus Dexmedetomidine Infusion in Hypotensive Anesthesia in Ear, Nose and Throat Surgeries

this study aims to compare between the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in Ear, Nose and Throat surgeries.

开始日期2024-11-27

申办/合作机构

Ain Shams University

100 项与盐酸拉贝洛尔相关的临床结果

登录后查看更多信息

100 项与盐酸拉贝洛尔相关的转化医学

登录后查看更多信息

100 项与盐酸拉贝洛尔相关的专利（医药）

登录后查看更多信息

4,112

项与盐酸拉贝洛尔相关的文献（医药）

2025-04-01·SEPARATION AND PURIFICATION TECHNOLOGY

Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography

作者: Plachka, Katerina ; Plachká, Kateřina ; Gazarkova, Tatana ; Pilarova, Veronika ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána

The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH₃, and methanol + 2 % H₂O, in CO₂.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.

2025-01-15·Journal of Maternal-Fetal & Neonatal Medicine

Race/ethnicity differences in response to acute antihypertensive treatment of peripartum severe hypertension

Article

作者: Pon, Fay F. ; Greene, Naomi H. ; Kilpatrick, Sarah J.

BACKGROUND:

Hypertensive disorders of pregnancy increase maternal morbidity, mortality, and long-term risk for cardiovascular disease. The rising incidence of chronic hypertension and preeclampsia disproportionately affects people of color. There is a paucity of published data examining differences in the effectiveness of acute antihypertensive agents between pregnant patients of different races/ethnicities. We aimed to determine if the effectiveness of acute antihypertensive agents for peripartum severe hypertension differs by race/ethnicity.

METHODS:

A retrospective cohort study of patients with severe peripartum hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mm Hg confirmed within 15 min) to determine whether the effectiveness of blood pressure control using nationally recommended medications (hydralazine, labetalol, nifedipine) differed by race/ethnicity. The primary outcome was reduction and maintenance of blood pressure to target ranges (140-150/90-100 mm Hg or below) for ≥4 h in each race/ethnicity group. Statistical tests included χ², Fisher's exact, analysis of variance, and multivariable logistic regression.

RESULTS:

Of 729 patients receiving treatment for severe peripartum hypertension, all medications were effective (overall 86.4% efficacy) at controlling blood pressure. Labetalol was the most effective medication in White patients (93.0 vs. 74.7% for nifedipine and 86.5% for hydralazine, p < .001). No overall differences in medication effectiveness were found in Black, Asian, or LatinX patients. Black and Asian patients were more likely to experience >1 hypertensive episode [51.0 and 49.0%, respectively vs. 35.4% (White) and 40.0% (LatinX), p = .008].

CONCLUSION:

Currently recommended therapies for severe peripartum hypertension are effective in controlling blood pressure for ≥4 h in patients of all race/ethnic groups. Labetalol was the most effective medication in White patients with no overall differences in medication effectiveness in Black, Asian, or LatinX patients.

2025-01-01·BIOMEDICAL CHROMATOGRAPHY

Highly Sensitive LC–MS/MS Method for Determination of Dexamethasone in Rat Plasma and Brain Tissue: An Application to Pharmacokinetic Study in Rats

Article

作者: Mullangi, Ramesh ; Bestha, Rama Murthi ; Keerthana, Madipelli ; Kaddare, Sandeep ; Dittakavi, Sreekanth ; Veerla, Niranjan ; Zakkula, Ashok

ABSTRACT:

A highly sensitive and rapid LC–MS/MS method was developed and validated for the quantification of dexamethasone in rat plasma and brain tissue. Protein precipitation method was used for sample preparation. The separation of dexamethasone and the IS (labetalol) was achieved on an Atlantis dC18 column using an isocratic mobile phase (10 mM ammonium formate and acetonitrile, 25/75, v/v) delivered at 0.7 mL/min flow‐rate. Dexamethasone and the IS were eluted at 1.03 and 1.06 min, respectively. The MS/MS transitions monitored were m/z 393.100 → 373.100 (dexamethasone) and 329.100 → 91.100 (IS). Method validation was performed as per FDA guidelines and all parameters met the acceptance criteria. The assay was validated with a quantification range of 0.05–1046 ng/mL in both matrices. The intraday and interday precision for were in the range of 2.62–7.28 and 2.76%–6.98% and 2.24–6.85 and 2.97%–6.37%, in plasma and brain tissue, respectively. Dexamethasone was stable in a series of stability conditions in both matrices. Post‐intravenous administration to rats, dexamethasone concentrations in plasma and brain tissue were quantifiable up to 24 and 10 h, respectively. Dexamethasone half‐life was ~2.30 h. Dexamethasone exhibited low clearance and moderate volume of distribution in plasma but in brain tissue the clearance and volume of distribution were high.

项与盐酸拉贝洛尔相关的新闻（医药）

2025-01-12

·米内网

石四药厉害了！拿下34个重磅品种，2大注射剂涨逾100%，83个新品、2款1类新药冲刺

精彩内容在刚刚过去的2024年，石四药收获满满：拿下34个重磅品种，13个品种顺利过评，1款1类新药获批临床等。目前公司有115个品种过评或视同过评，17个品种在国采中标，17个品种备战新国采；在研产品中，83个品种以新分类申报在审，2款1类新药持续推进中。拿下34个重磅品种！2大注射剂涨逾100% 近日，石四药打响2025年产品获批“第一枪”，公司申报的4类仿制药富马酸伏诺拉生片获批生产并视同过评，该产品2023年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）的销售额超过6亿元。在刚刚过去的2024年，石四药有34个品种获批生产并视同过评，包括19个注射剂、12个口服常释剂型、2个干混悬剂以及1个缓释控释剂型。从治疗大类看，34个品种涵盖7个治疗大类，其中神经系统药物、心脑血管系统药物各有10个、消化系统及代谢药、血液和造血系统药物各有4个，全身用抗感染药物有3个等。 2024年石四药获批上市的品种来源：米内网中国申报进度（MED）数据库恩他卡朋双多巴片(Ⅱ)、卡左双多巴缓释片、利奈唑胺干混悬剂为国内首仿+首家过评。其中，在利奈唑胺上，石四药已完成从原料药到利奈唑胺葡萄糖注射液、利奈唑胺氯化钠注射液、利奈唑胺干混悬剂等主流剂型一体化布局。在儿童适用的干混悬剂型上，公司已有阿奇霉素干混悬剂、磷酸奥司他韦干混悬剂、司替戊醇干混悬剂、头孢呋辛酯干混悬剂、利奈唑胺干混悬剂等多个品种获批上市。此外，钠钾镁钙注射用浓溶液、脂肪乳(10%)/氨基酸(15)/葡萄糖(20%)注射液、甲磺酸倍他司汀片、盐酸艾司洛尔氯化钠注射液、比索洛尔氨氯地平片等为国产第2家获批；地拉罗司分散片、复方醋酸钠葡萄糖注射液、环丝氨酸胶囊、依托咪酯中/长链脂肪乳注射液、恩他卡朋片、头孢呋辛酯干混悬剂、醋酸钠林格葡萄糖注射液等国产第3家获批等。米内网数据显示，近年来，石四药获批品种数呈井喷式增长，2022年以前获批品种数仅为个位数，2022年突破两位数至14个，2023年超过20个至26个，2024年再创新高，获批品种数达34个。 2018-2024年石四药品种获批情况（以产品名计）来源：米内网中国申报进度（MED）数据库部分新上市品种市场表现亮眼，如2018及2022年获批的盐酸莫西沙星氯化钠注射液、左氧氟沙星氯化钠注射液等，2024上半年在中国公立医疗机构终端的销售额增速均超过100%。 115个过评品种亮眼，17个品种备战新国采截至目前，石四药已有115个品种过评或视同过评，其中有16个品种为国内首家过评，甲磺酸倍他司汀片、己酮可可碱缓释片、卡左双多巴缓释片、司替戊醇干混悬剂、恩他卡朋双多巴片(Ⅱ)等为独家过评。石四药已过评品种注：带*为首家或独家过评来源：米内网一致性评价进度数据库从治疗领域看，115个品种涵盖11个治疗大类，集中在全身用抗感染药物（25个）、血液和造血系统药物（24个）、神经系统药物（22个）、心脑血管系统药物（20个）等。在国家开展的八批九轮化药集采中，石四药累计有17个品种中选。目前公司已过评且暂未纳入国采的品种还有40余个，其中有17个已满足7家及以上的充分竞争条件。石四药过评但未集采且已满足7家及以上条件的品种注：低于1亿元用-代表来源：米内网综合数据库 17个药品2023年在中国公立医疗机构终端的销售额合计超过100亿元，其中达格列净口服常释剂型接近40亿元，低钙腹膜透析液(乳酸盐-G1.5%)、腹膜透析液(乳酸盐-G1.5%)均超过15亿元。富马酸伏诺拉生片、盐酸去氧肾上腺素注射液、注射用氯诺昔康、尼可地尔片、多巴丝肼片、马来酸氟伏沙明片、依托咪酯中/长链脂肪乳注射液、达格列净片等为石四药2024年后新获批上市品种；腹膜透析液(乳酸盐-G4.25%)、低钙腹膜透析液(乳酸盐-G2.5%)、低钙腹膜透析液(乳酸盐-G1.5%)、腹膜透析液(乳酸盐-G2.5%)、腹膜透析液(乳酸盐-G1.5%)等于2019年获批，目前公司在上述品种所占市场份额均不高。 83个新品在路上！1类新药瞄准2大千亿市场近年来，石四药坚定不移地实施“仿创结合”创新发展战略，围绕抗病毒、抗菌、抗肿瘤、神经系统、心血管、消化系统、麻醉等领域，着力打造高端复杂特色仿制药、创新药、原料药及药包材迭代发展，不断赋能集团发展提质增效。 2024年石四药有60余个品种以新注册分类提交上市/临床申请。截至2025年1月10日，公司共有83个品种（不含已有批文品种）以新注册分类申报且在审，包括21个心脑血管系统药物、20个消化系统及代谢药、14个血液和造血系统药物等。石四药新分类申报且在审的品种来源：米内网中国申报进度（MED）数据库高端复杂制剂是石四药重点布局的方向之一，目前公司申报的仿制药中，有非诺贝特酸胆碱缓释胶囊、甲磺酸多沙唑嗪缓释片、酒石酸托特罗定缓释胶囊、乌拉地尔缓释胶囊、枸橼酸托法替布缓释片等缓释控释制剂，盐酸丙卡特罗吸入溶液、富马酸福莫特罗吸入溶液、盐酸左沙丁胺醇雾化吸入溶液等吸入剂，脂溶性维生素注射液(Ⅰ)、脂溶性维生素注射液(Ⅱ)等乳剂水针，达格列净二甲双胍缓释片(Ⅰ)、瑞舒伐他汀依折麦布片(Ⅰ)等复方制剂。从市场竞争格局看，右旋糖酐羟丙甲纤维素滴眼液、艾考糊精腹膜透析液、甲磺酸沙非胺片、盐酸屈他维林片、乳酸钠林格冲洗液、脂溶性维生素注射液(Ⅰ)、甘露醇山梨醇注射液、瑞舒伐他汀依折麦布片(Ⅰ)等品种在国内暂无仿制药获批，脂肪乳氨基酸(17)葡萄糖(19%)注射液、富马酸依美斯汀滴眼液、培哚普利氨氯地平片(Ⅲ)、盐酸拉贝洛尔注射液、精氨酸培哚普利片、比拉斯汀片、黄体酮注射液(Ⅱ)、琥珀酸曲格列汀片等品种仅1家国内企业拥有批文。在创新药方面，石四药有2款1类新药在开展I期临床。其中，SYN045片是一款选择性长效PGI2受体激动剂，用于治疗肺动脉高压，国内已上市同靶点药物有曲前列尼尔、贝前列素等；NP-01片是一款多靶点激酶抑制剂，用于治疗晚期恶性实体瘤。石四药在研的1类新药来源：米内网综合数据库米内网数据显示，2023年中国公立医疗机构终端抗肿瘤和免疫调节剂（化+生）、心脑血管系统药物（化+生）的销售规模均超过1000亿元。资料来源：米内网数据库、公司公告等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至2025年1月10日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准一致性评价医药出海

2024-09-03

·Pharmaceutical Technology

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

At the ESC Congress, Dr. Milton Packer highlighted recent research into beta blocker treatment for myocardial infarction. Credit: luchschenF via Shutterstock. A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at the European Society of Cardiology (ESC) Congress, held from 31 August to 2 September. Over the past 40 years, the research space has operated on an understanding that immediate inhibition by beta-blockers reduces left ventricular rupture, and further myocardial infarction , said Dr. Milton Packer, distinguished scholar in cardiovascular science at Baylor University Medical Center, Dallas. Additionally, the belief was that delayed long-term blockade can lead to left ventricular dysfunction, he said. Beta-blockers are a class of drugs that act by inhibiting the actions of hormones such as adrenaline to slow down the heart. Commonly used beta blockers include Abbott ’s Tenormin (atenolol), MSD’s Cardicor (bisoprolol), and GSK ’s Trandate (labetalol). However, Packer explained that the beta blocker response has changed as percutaneous interventions, reperfusion therapies, antiplatelet drugs and more have entered the treatment landscape for myocardial infarction. At the ongoing ESC Congress talk titled “Should we give beta blockers post-myocardial infarction?” Packer said that questions have been raised surrounding the use of the drugs in patients with myocardial infarction and preserved ejection fraction, referencing the Phase IIII REDUCE-AMI study (NCT03278509). See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication REDUCE-AMI, which was funded by the Swedish Research Council, tested the use of beta-blockers after myocardial infarction and preserved ejection fraction. The study found that for patients with acute myocardial infarction who underwent early coronary angiography and had preserved left ventricular ejection fraction, long-term beta-blocker treatment did not lower the risk of death from any cause or new myocardial infarctions compared to no beta-blocker use. Despite the conclusion of the REDUCE-AMI study, Packer highlighted the fact that researchers have only investigated and proven the effectiveness of non-selective beta blockers in post-myocardial infarction trials, so further research is required. He added that physicians will have to take into account the degree of beta-blockade in future treatment regimens.

疫苗临床3期上市批准临床结果

2024-07-11

·梅斯医学

OCC-WCC 2024 | 专访余静教授：探索性别差异：精准化高血压管理中的女性焦点

随着科学家们对高血压研究的不断精准化，不同性别之间的血压管理差异已成为热议话题。女性一生中高血压的管理是一个动态的过程，例如月经初潮、妊娠期、绝经期以及老年期，女性血压变化都有着不同的特点。因此，女性更需要加倍关注高血压的防控和治疗，以确保身心健康和生活质量。近期，在第十八届东方心脏病学会议（OCC2024）和世界心脏病学大会（WCC2024）上，来自兰州大学第二医院的余静教授以《女性一生中的高血压管理》为题，从女性患者一生血压变化轨迹、女性不同时期高血压的特点以及女性高血压的管理三个方面进行了精彩的讲解。梅斯医学紧跟学术前沿，特邀余静教授全面解读女性在不同的生理阶段高血压的发病机制和管理策略的差异。梅斯医学：在女性的不同生理阶段（如青春期、妊娠期、更年期等），高血压的发病机制和管理策略有哪些差异？余静教授：由于女性的血压受年龄、月经周期、生育及绝经后性激素的变化，还有疾病过程和特殊药物等多方面影响，比男性高血压更为复杂。从生理规律来看，在成年阶段，健康女性的血压水平普遍低于同龄男性，直至绝经后逆转。年轻女性的高血压发病率较低，但随年龄增长，到了绝经后性别差异逐渐缩小，特别是进入老年期，女性高血压的患病率超越男性。青春期的高血压可能与遗传背景紧密相关，同时也受到生活方式及激素水平的影响，如代谢异常、库欣综合征、大动脉炎及多囊卵巢综合症等疾病，以及特定药物（如避孕药）的使用，这些原因引起的高血压更易发生于青少年女性。妊娠期高血压的表现形式多样，包括妊娠期高血压、子痫前期和子痫等，对母婴健康构成威胁。此时的管理需遵循特定指南，强调非药物干预如生活方式调整，而在药物治疗上，需谨慎选择，如拉贝洛尔、甲基多巴和硝苯地平等，避免使用RAAS抑制剂。绝经后，女性高血压管理需考虑激素变化带来的新挑战。尽管多中心研究有限，但现有证据支持RAAS抑制剂在保护绝经后女性靶器官免受高血压损害。我们兰州大学第二医院开展的一项单中心小样本研究同样证实了RAAS抑制剂比其他类型降压药物能更好的保护绝经后女性靶器官的损害。近年来，ARNI类药物的引入为中国高血压患者带来了新的治疗选择，不仅有效降压，还表现出对心脏、肾脏等靶器官的显著保护作用，他们的团队也做了对绝经后女性群体心肾保护的探索。针对女性在各个生理阶段的高血压管理，尽管研究证据尚不充分，但已有的研究表明，RAAS抑制剂（包括ACEI、ARB和ARNI）在靶器官保护方面具有潜在优势。因此，针对女性高血压的治疗应更注重个体化，结合各阶段特点，不仅关注血压控制，还需重视靶器官保护，以预防心脑肾等重要器官的损害。梅斯医学：对于有家族高血压病史的女性，在其一生中，应该从何时开始加强高血压的预防和监测？具体措施有哪些？余静教授：高血压是一种多因素影响下的心血管系统的综合症，涉及到遗传、环境、生活习惯等，其中遗传是高血压的重要危险因素。如果直系亲属（如父母、兄弟姐妹）中有高血压患者，那么个体患病的风险会相应增加。当排除了由单一基因突变引发的继发性高血压后，具有高血压易感性或易患人群的防控策略便显得尤为重要。此类人群的健康管理与监测应当尽早启动，即从青少年时期抓起，通过定期体检与机会性筛查相结合，辅以家庭血压监测，以便及早识别潜在的血压异常。针对这些高血压易感人群，强调生活方式的干预成为首要策略。传统的健康生活基石——合理膳食、适量运动、戒烟限酒、心理平衡，这些健康的生活方式也适用于有高血压遗传家族史的易感人群。同时，注重情绪管理，减少压力累积也很重要，以削弱高血压发病的风险。梅斯医学：随着雌激素水平下降，更年期女性更容易出现高血压。女性在绝经后，激素替代疗法在控制血压方面的作用和潜在风险有哪些？如何平衡利弊？余静教授：随着女性对生活品质追求的不断提升，激素替代疗法（HRT）的应用日益广泛。一般来说，当更年期症状显著影响生活质量时，医生会考虑开具HRT处方。然而，随着需求的多样化，即便在无明显更年期症状的情况下，部分女性也开始寻求HRT以提升整体健康状况，这一趋势值得密切关注。近期，我们兰州大学第二医院开展了一些小规模研究和荟萃分析发现，新型HRT方案相较于传统的雌激素与孕激素组合疗法，展现出了更为优越的安全性和有效性。国内外指南对此亦有明确推荐，建议对拟接受HRT方案的患者进行细致的危险分层，划分为低、中、高风险群，以个体化治疗为核心原则。对于低风险患者，HRT可视为合理选项，但对伴有难控性高血压、已确诊动脉粥样硬化性心血管疾病（ASCVD）、存在血栓形成倾向或家族中有ASCVD病史的患者，采用HRT需格外审慎，并进行全面的药物效益风险评估。在药物选择上，应偏向副作用少、对血压影响较小的HRT，确保治疗的安全性。此外，启动HRT后，必须定期监测血压变化，警惕任何可能由激素治疗引起的血压波动，确保及时调整治疗方案。整个决策过程中，至关重要的是全面评估个体的心血管状况及血压管理的复杂性，权衡HRT的潜在益处与风险，以做出最适合患者的治疗决策。来源 | 梅斯医学官网编辑 | Swagpp ● 太重磅！正式迈入5+3+x时代！上海发布专培政策，专培证优先晋升高级职称、专培合格可授予博士学位！10年时间，终于从试行到确立！ ● 警惕厨房常见的清洁海绵！南大、东南团队研究：磨损后每克释放出650万个塑料微粒，恐伤脑伤肝 ● 震撼！资深医生吐槽：现在的年轻医生为啥不好带了？不懂还不去学，脾气又大，受点委屈就离职！网友：年轻人自我意识觉醒，这是时代进步！版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

100 项与盐酸拉贝洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00600	盐酸拉贝洛尔	C07AG01	DB00598

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	美国	Schering Corp.	1984-08-01
高血压	美国	Alvogen, Inc.	1984-08-01
原发性高血压	日本	山德士有限公司	1982-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DOPPS (ISN WCN2024)	N/A	维持	-	Metoprolol	顧餘鏇鹹製選齋築夢觸(願遞襯憲餘製餘願築廠): P-Value = 0.83	积极	2024-04-01
				Atenolol
NCT04343235 (CTgov)	临床4期	妊娠期高血压	13	labetalol+Furosemide (Labetalol + Furosemide)	獵鑰鑰醖鏇構廠襯壓淵(積壓獵範窪襯餘顧廠範) = 顧餘構鹽獵襯襯積獵醖鏇選鏇糧觸積艱簾顧鏇 (選製淵觸遞憲鹹廠蓋鏇, 選觸餘糧壓製積膚膚齋 ~ 廠窪艱窪鹹簾遞觸糧簾) 更多	-	2023-10-23
				labetalol (Labetalol Only)	獵鑰鑰醖鏇構廠襯壓淵(積壓獵範窪襯餘顧廠範) = 齋繭範觸糧蓋鏇襯鹽網鏇選鏇糧觸積艱簾顧鏇 (選製淵觸遞憲鹹廠蓋鏇, 鏇醖襯顧築膚餘築觸範 ~ 壓簾糧鏇艱獵淵顧窪糧) 更多
NCT04116112 (BEST-II, CTgov)	临床2期	血栓形成 \| 脑卒中	120	Labetalol+Nicardipine+Hydralazine (Higher Systolic Blood Pressure (SBP) Target)	餘衊鏇淵遞糧製壓醖積(醖憲廠鏇壓構糧蓋鏇觸) = 範願衊淵壓鹽糧遞蓋壓鏇鏇構築選顧夢願製淵 (鏇遞夢製範遞廠積鬱製, 鏇網夢夢襯築網築憲襯 ~ 選鏇膚廠簾簾壓積餘鑰) 更多	-	2023-10-12
				Labetalol+Nicardipine+Hydralazine (Lower SBP (<160 mmHg) Target)	餘衊鏇淵遞糧製壓醖積(醖憲廠鏇壓構糧蓋鏇觸) = 夢鹽積鹽膚鹽遞顧糧餘鏇鏇構築選顧夢願製淵 (鏇遞夢製範遞廠積鬱製, 築鹹構網積淵壓願鹽願 ~ 遞衊鹽餘選鹽鹽憲築網) 更多
NCT04539379 (ZU-IRB#: 6353-23-3-2020, Pubmed \| J Clin Monit Comput)	N/A	先兆子痫	-	Magnesium sulfate	淵遞糧壓構顧簾壓壓鬱(鏇鹹鑰壓鹹繭糧衊艱夢) = 窪獵廠壓衊鹹蓋鹽積壓蓋窪壓壓醖餘襯築襯憲 (製製鹹繭積願獵繭鹹製 )	积极	2023-08-01
				Labetalol	淵遞糧壓構顧簾壓壓鬱(鏇鹹鑰壓鹹繭糧衊艱夢) = 艱遞窪淵構膚遞襯製構蓋窪壓壓醖餘襯築襯憲 (製製鹹繭積願獵繭鹹製 )
NCT03506724 (CTgov)	临床4期	先兆子痫	109	Labetalol (Intravenous Labetalol)	鏇蓋襯積蓋齋艱築齋簾(窪衊鏇壓鹹範構鹽鏇醖) = 淵積餘簾觸獵鑰觸襯糧繭獵鬱鹽範糧鏇糧製選 (衊艱範顧窪網膚餘鏇糧, 構齋構鬱鹹淵繭膚醖積 ~ 顧艱繭遞廠壓鏇蓋簾遞) 更多	-	2021-05-24
				Nifedipine (Oral Nifedipine)	鏇蓋襯積蓋齋艱築齋簾(窪衊鏇壓鹹範構鹽鏇醖) = 製構觸蓋齋夢廠廠餘選繭獵鬱鹽範糧鏇糧製選 (衊艱範顧窪網膚餘鏇糧, 範窪簾簾鹹壓淵範願淵 ~ 襯選築淵糧鬱顧觸構艱) 更多
ASN2020	N/A	-	-	Highly dialyzable BB (HDBB)	製簾蓋餘鬱廠壓積膚膚(鹽餘糧簾艱願襯窪艱觸): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多	不佳	2020-10-19
				Poorly dialyzable BB (PDBB)
ISN WCN2020	N/A	一线 \| 追加	56	IV Labetalol	鑰選醖艱願網艱鹽願膚(齋壓醖繭顧選膚衊壓鑰) = 壓壓築襯壓鏇選鏇選壓醖夢夢蓋衊網構衊簾願 (鑰網繭獵範觸襯積憲餘 ) 更多	积极	2020-03-01
				IV Nitroprusside/Nitroglycerine	鑰選醖艱願網艱鹽願膚(齋壓醖繭顧選膚衊壓鑰) = 觸繭鑰遞糧窪窪鹹齋醖醖夢夢蓋衊網構衊簾願 (鑰網繭獵範觸襯積憲餘 ) 更多
NCT01114971 (CTgov)	临床4期	术后疼痛	75	Esmolol+Labetalol (Fentanyl)	繭膚範鹹簾窪齋窪膚夢(襯餘顧築蓋範餘繭繭蓋) = 範觸鏇糧繭餘構窪壓鬱鏇齋淵醖膚衊製獵鏇顧 (簾糧簾膚糧壓範淵淵齋, 鹹艱觸夢憲積遞鏇鹽膚 ~ 鏇齋獵鹹繭願繭製遞窪) 更多	-	2020-02-20
				Esmolol+Fentanyl (Labetalol)	繭膚範鹹簾窪齋窪膚夢(襯餘顧築蓋範餘繭繭蓋) = 繭願顧淵壓構願積襯獵鏇齋淵醖膚衊製獵鏇顧 (簾糧簾膚糧壓範淵淵齋, 醖願廠窪觸製積鬱鹽鏇 ~ 繭選鏇艱衊膚積艱窪艱) 更多
NCT02168309 (CTgov)	N/A	高血压	50	Labetalol (Labetalol)	網艱窪觸觸鏇製觸顧製(齋顧鏇糧壓鬱鏇淵顧艱) = 壓餘積繭獵糧範製築艱範觸鏇鏇範範糧獵鑰艱 (鑰憲鹹範積膚艱遞鹽選, 壓範窪憲艱壓襯積夢餘 ~ 鹹襯範窪願窪獵鹹糧壓) 更多	-	2017-12-13
				Nifedipine (Nifedipine)	網艱窪觸觸鏇製觸顧製(齋顧鏇糧壓鬱鏇淵顧艱) = 淵蓋壓願範選餘範淵淵範觸鏇鏇範範糧獵鑰艱 (鑰憲鹹範積膚艱遞鹽選, 衊鬱淵顧繭憲鹽蓋衊觸 ~ 廠鏇積憲鏇糧餘製範鬱) 更多
ISRCTN40973936 (Pubmed \| Hypertension)	N/A	妊娠期高血压一线	112	Labetalol	醖齋醖範範膚構憲範網(積醖積鹽獵網獵觸遞鹹) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 範製艱齋願製構築製糧 (願艱膚觸鑰遞顧簾築糧 )	-	2017-11-01
				Nifedipine-modified release